Asthma from immune pathogenesis to precision medicine
- PMID: 31387788
- DOI: 10.1016/j.smim.2019.101294
Asthma from immune pathogenesis to precision medicine
Abstract
Asthma is characterized by multiple immunological mechanisms (endotypes) determining variable clinical presentations (phenotypes). The identification of endotypic mechanisms is crucial to better characterize patients and to identify tailored therapeutic approaches with novel biological agents targeting specific immunological pathways. This review focused on summarizing the major immunological mechanisms involved in the pathogenesis of asthma, as well as on discussing the emergence of phenotypic features of the disease. Novel biological agents and other drugs targeting specific endotypes are discussed, as their use represent a precision medicine approach to the disease that is nowadays mandatory particularly for treating more severe patients.
Keywords: Adaptive immunity; Asthma; Endotypes; Innate immunity; Phenotypes; Precision medicine.
Copyright © 2019 Elsevier Ltd. All rights reserved.
Similar articles
-
Recent Advances in Severe Asthma: From Phenotypes to Personalized Medicine.Chest. 2020 Mar;157(3):516-528. doi: 10.1016/j.chest.2019.10.009. Epub 2019 Oct 31. Chest. 2020. PMID: 31678077 Free PMC article. Review.
-
Personalized medicine with biologics for severe type 2 asthma: current status and future prospects.MAbs. 2018 Jan;10(1):34-45. doi: 10.1080/19420862.2017.1392425. Epub 2017 Nov 14. MAbs. 2018. PMID: 29035619 Free PMC article. Review.
-
Real-life studies of biologics used in asthma patients: key differences and similarities to trials.Expert Rev Clin Immunol. 2019 Sep;15(9):951-958. doi: 10.1080/1744666X.2019.1653758. Epub 2019 Aug 12. Expert Rev Clin Immunol. 2019. PMID: 31389304 Review.
-
Severe asthma phenotypes and endotypes.Semin Immunol. 2019 Dec;46:101301. doi: 10.1016/j.smim.2019.101301. Epub 2019 Aug 27. Semin Immunol. 2019. PMID: 31466925 Review.
-
Controversies and opportunities in severe asthma.Curr Opin Pulm Med. 2018 Jan;24(1):83-93. doi: 10.1097/MCP.0000000000000438. Curr Opin Pulm Med. 2018. PMID: 29059087 Review.
Cited by
-
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13.Vaccines (Basel). 2022 Jun 19;10(6):974. doi: 10.3390/vaccines10060974. Vaccines (Basel). 2022. PMID: 35746582 Free PMC article. Review.
-
A prognosis prediction chromatin regulator signature for patients with severe asthma.Allergy Asthma Clin Immunol. 2023 May 27;19(1):43. doi: 10.1186/s13223-023-00796-1. Allergy Asthma Clin Immunol. 2023. PMID: 37245015 Free PMC article.
-
Harmonising cellular conversations: decoding the vital roles of extracellular vesicles in respiratory system intercellular communications.Eur Respir Rev. 2024 Nov 13;33(174):230272. doi: 10.1183/16000617.0272-2023. Print 2024 Oct. Eur Respir Rev. 2024. PMID: 39537245 Free PMC article. Review.
-
Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies.Drug Des Devel Ther. 2021 Mar 23;15:1275-1284. doi: 10.2147/DDDT.S300988. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 33790539 Free PMC article. Review.
-
Novel Biological Therapies for Severe Asthma Endotypes.Biomedicines. 2022 May 4;10(5):1064. doi: 10.3390/biomedicines10051064. Biomedicines. 2022. PMID: 35625801 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical